LymphedemaV1, PascalFrancis, Curation, bibRecord, 000345

Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study

Identifieur interne : 000345 ( PascalFrancis/Curation ); précédent : 000344; suivant : 000346

Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study

Auteurs : R. V. Cluzan [France] ; A. P. Pecking [France] ; H. Mathiex-Fortunet [France] ; E. Léger Picherit [France]

Source :

Lymphology [ 0024-7766 ] ; 2004.

RBID : Pascal:04-0599834

Descripteurs français

Pascal (Inist)
- Appareil circulatoire pathologie, Membre supérieur, Lymphatique pathologie, Tumeur maligne, Lymphoedème, Cancer du sein.

English descriptors

KwdEn :
- Breast cancer, Cardiovascular disease, Lymphatic vessel disease, Lymphedema, Malignant tumor, Upper limb.

Abstract

The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.

A01	`01`	`1`		`@0 0024-7766`
A02	`01`			`@0 LYMPBN`
A03		`1`		`@0 Lymphology`
A05				`@2 37`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study`
A11	`01`	`1`		`@1 CLUZAN (R. V.)`
A11	`02`	`1`		`@1 PECKING (A. P.)`
A11	`03`	`1`		`@1 MATHIEX-FORTUNET (H.)`
A11	`04`	`1`		`@1 PICHERIT (E. Léger)`
A14	`01`			`@1 Hospital Cognacq-Jay @2 Paris @3 FRA @Z 1 aut.`
A14	`02`			`@1 Centre René Huguenin @2 Paris @3 FRA @Z 2 aut.`
A14	`03`			`@1 Beaufour Ipsen Pharma @2 Paris @3 FRA @Z 3 aut. @Z 4 aut.`
A20				`@1 47-52`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 14604 @5 354000114008510030`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 7 ref.`
A47	`01`	`1`		`@0 04-0599834`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Lymphology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.
C02	`01`	`X`		`@0 002B12B04`
C02	`02`	`X`		`@0 002B12B03`
C02	`03`	`X`		`@0 002B27B03`
C03	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Membre supérieur @5 02`
C03	`02`	`X`	`ENG`	`@0 Upper limb @5 02`
C03	`02`	`X`	`SPA`	`@0 Miembro superior @5 02`
C03	`03`	`X`	`FRE`	`@0 Lymphatique pathologie @5 04`
C03	`03`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 04`
C03	`03`	`X`	`SPA`	`@0 Linfático patología @5 04`
C03	`04`	`X`	`FRE`	`@0 Tumeur maligne @5 07`
C03	`04`	`X`	`ENG`	`@0 Malignant tumor @5 07`
C03	`04`	`X`	`SPA`	`@0 Tumor maligno @5 07`
C03	`05`	`X`	`FRE`	`@0 Lymphoedème @5 10`
C03	`05`	`X`	`ENG`	`@0 Lymphedema @5 10`
C03	`05`	`X`	`SPA`	`@0 Linfedema @5 10`
C03	`06`	`X`	`FRE`	`@0 Cancer du sein @4 CD @5 96`
C03	`06`	`X`	`ENG`	`@0 Breast cancer @4 CD @5 96`
C03	`06`	`X`	`SPA`	`@0 Cáncer del pecho @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Glande mammaire pathologie @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 37`
N21				`@1 348`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000615

Links to Exploration step

Pascal:04-0599834

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study</title>
<author><name sortKey="Cluzan, R V" sort="Cluzan, R V" uniqKey="Cluzan R" first="R. V." last="Cluzan">R. V. Cluzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hospital Cognacq-Jay</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A. P." last="Pecking">A. P. Pecking</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre René Huguenin</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mathiex Fortunet, H" sort="Mathiex Fortunet, H" uniqKey="Mathiex Fortunet H" first="H." last="Mathiex-Fortunet">H. Mathiex-Fortunet</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Beaufour Ipsen Pharma</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Picherit, E Leger" sort="Picherit, E Leger" uniqKey="Picherit E" first="E. Léger" last="Picherit">E. Léger Picherit</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Beaufour Ipsen Pharma</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0599834</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0599834 INIST</idno>
<idno type="RBID">Pascal:04-0599834</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000615</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000345</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study</title>
<author><name sortKey="Cluzan, R V" sort="Cluzan, R V" uniqKey="Cluzan R" first="R. V." last="Cluzan">R. V. Cluzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hospital Cognacq-Jay</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Pecking, A P" sort="Pecking, A P" uniqKey="Pecking A" first="A. P." last="Pecking">A. P. Pecking</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre René Huguenin</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mathiex Fortunet, H" sort="Mathiex Fortunet, H" uniqKey="Mathiex Fortunet H" first="H." last="Mathiex-Fortunet">H. Mathiex-Fortunet</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Beaufour Ipsen Pharma</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Picherit, E Leger" sort="Picherit, E Leger" uniqKey="Picherit E" first="E. Léger" last="Picherit">E. Léger Picherit</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Beaufour Ipsen Pharma</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lymphology</title>
<title level="j" type="abbreviated">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lymphology</title>
<title level="j" type="abbreviated">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast cancer</term>
<term>Cardiovascular disease</term>
<term>Lymphatic vessel disease</term>
<term>Lymphedema</term>
<term>Malignant tumor</term>
<term>Upper limb</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Appareil circulatoire pathologie</term>
<term>Membre supérieur</term>
<term>Lymphatique pathologie</term>
<term>Tumeur maligne</term>
<term>Lymphoedème</term>
<term>Cancer du sein</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0024-7766</s0>
</fA01>
<fA02 i1="01"><s0>LYMPBN</s0>
</fA02>
<fA03 i2="1"><s0>Lymphology</s0>
</fA03>
<fA05><s2>37</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CLUZAN (R. V.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PECKING (A. P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MATHIEX-FORTUNET (H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PICHERIT (E. Léger)</s1>
</fA11>
<fA14 i1="01"><s1>Hospital Cognacq-Jay</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centre René Huguenin</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Beaufour Ipsen Pharma</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>47-52</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>14604</s2>
<s5>354000114008510030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>7 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0599834</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Lymphology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The purpose of this study was to determine whether BN165 (Ginkor Fort), which has been reported to alleviate symptoms of venous insufficiency, has a beneficial effect on lymphatic function or lymphedema symptoms. Using a 3-arm, double-blind, placebo-controlled design in 48 patients with upper extremity lymphedema secondary to breast cancer treatment, improvement in symptoms and signs as well as lymphoscintigraphic kinetic parameters (radiocolloid half-life and lymphatic migration speed) was assessed in response to treatment. A statistically significant effect on limb heaviness was noted. Lymphatic migration speed also demonstrated a significant increase at a dose of 2 active capsules per day but not at the 3 capsules per day dose, but lymphatic migration speed also improved in the placebo group. These findings in mechanical lymphatic insufficiency in breast cancer-related lymphedemas can be compared to the previously published clinical amelioration by BN165 of the subjective symptoms (heavy limbs) of dynamic lymphatic insufficiency in patients with venous insufficiency. Further studies are needed to define the possible role of BN165 in treating patients with lymphedema.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12B03</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B27B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Membre supérieur</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Upper limb</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Miembro superior</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Breast cancer</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fN21><s1>348</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000345 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000345 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0599834
   |texte=   Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study

Effecacy of BN165 (Ginkor fort) in breast cancer related upper limb lymphedema: A preliminary study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri